Mystery of the environmental triggers for cancer deepens
Study shows that our knowledge of why tumours form is still inadequateScientists will have to rethink howenvironmental triggers allow tumours to form and develop, one of Britain ’s leading cancer experts warned last week. Michael Stratton, director of the Wellcome Sanger Institute, said recent results from an international cancer research study – which aimed to pinpoint environmental triggers involved in oeosophageal cancer – indicated current scientific understanding of tumour formation was inadequate.The research – on a type known as oesophageal squamous cell carcinoma – was aimed at uncover...
Source: Guardian Unlimited Science - October 24, 2021 Category: Science Authors: Robin McKie Tags: Cancer research Medical research UK news Science Source Type: news

New Opdivo/Yervoy Mesothelioma Clinical Trial Begins Soon
A novel clinical trial involving the immunotherapy combination of Opdivo and Yervoy will open soon in Chicago. The goal is to study the drugs’ efficacy when added to surgery for patients with peritoneal mesothelioma cancer. The single-center, phase II clinical trial follows a recent report detailing the impressive three-year effectiveness of the drug combination when used for unresectable pleural mesothelioma. Bristol Myers Squibb manufactures Opdivo and Yervoy, known generically as nivolumab and ipilimumab. The U.S. Food and Drug Administration approved the combination for pleural mesothelioma in 2020, making ...
Source: Asbestos and Mesothelioma News - October 7, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

A Clinical and Biological Review of Keratoacanthoma A Clinical and Biological Review of Keratoacanthoma
Can keratoacanthomas be differentiated from cutaneous squamous cell carcinoma? This review compares the pathophysiology and clinical characteristics of the two, suggesting they are distinct entities.The British Journal of Dermatology (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2021 Category: Surgery Tags: Dermatology Journal Article Source Type: news

New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Human Papillomavirus-Associated Head and Neck Cancer Human Papillomavirus-Associated Head and Neck Cancer
Review the epidemiology, screening, presentation, diagnosis, prognosis, and prevention of HPV-positive oropharyngeal squamous cell carcinoma, with a focus on the primary care provider's role.Journal of the American Board of Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2021 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Guidance Issued for Preventing Cutaneous SCC in Solid Organ Recipients
WEDNESDAY, Sept. 1, 2021 -- In a consensus statement published online Sept. 1 in JAMA Dermatology, recommendations are presented for prevention strategies for cutaneous squamous cell carcinoma (CSCC) in solid organ transplant recipients... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2021 Category: Pharmaceuticals Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cutaneous Beta - HPV May Up Risk for Cutaneous Squamous Cell Carcinoma
Beta - HPV detected in skin swabs may predict cuSCC risk, but no link seen for serologic evidence of past beta - HPV infection (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 11, 2021 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Infections, Internal Medicine, Oncology, Pathology, Journal, Source Type: news

Cutaneous Beta-HPV May Up Risk for Cutaneous Squamous Cell Carcinoma
WEDNESDAY, Aug. 11, 2021 -- Cutaneous beta-human papillomavirus (HPV) may predict development of cutaneous squamous cell carcinoma (cuSCC), according to a study published online July 15 in Cancer Research. Dana E. Rollison, Ph.D., from the Moffitt... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 11, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

FDA Approves Expanded Indication for Merck ’s Keytruda (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)
Keytruda Is Now Approved for the Treatment of Patients With Recurrent or Metastatic or Locally Advanced cSCC That Is Not Curable by Surgery or Radiation KENILWORTH, N.J.--(BUSINESS WIRE) July 6, 2021 -- Merck (NYSE: MRK), known as MSD... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 6, 2021 Category: Drugs & Pharmacology Source Type: news

Consumer Health: UV radiation and your skin
July is UV Safety Month, which makes this a good time to learn more about the harmful effects of ultraviolet, or UV, radiation from sunlight or tanning beds. Skin cancer is the most common type of cancer, according to the American Cancer Society. Skin cancer develops primarily on areas of sun-exposed skin, including the scalp, face, lips, ears, neck, chest, arms, hands and legs.  The three main types of skin cancer are basal cell carcinoma, squamous cell carcinoma and melanoma.… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 4, 2021 Category: Databases & Libraries Source Type: news

Saliva Test to Detect HPV-Associated Throat Cancer Saliva Test to Detect HPV-Associated Throat Cancer
A new clinically validated saliva test has demonstrated high accuracy in detecting HPV-positive oropharyngeal squamous cell carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oncotarget: Infiltration in human skin squamous-cell carcinoma
(Impact Journals LLC) Over the last few years, oncology research is increasingly focused on the understanding of mutual interactions between cancer, stromal and immune cells in the tumor microenvironment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 7, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Lung squamous cell carcinoma tumors reveal therapeutic alterations
(Impact Journals LLC) " Lung cancer is the leading cause of cancer-related deaths across the globe with more than 1.7 million deaths annually. " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: E6-specific inhibitors as therapeutics for HPV+ head and neck carcinomas
(Impact Journals LLC) " Head and neck squamous cell carcinomas (HNSCC) are heterogeneous tumors that arise in the upper respiratory tract and are the 6th most common cancer worldwide by incidence. " (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news

Head and neck cancer cells hijack nearby healthy tissue, promoting further invasion of cancer cells
(University of Michigan) Up to half of patients with head and neck squamous cell carcinoma will experience tumor recurrence or new tumors--tumors that often spread and are difficult to treat. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 26, 2021 Category: Cancer & Oncology Source Type: news

ORIENT-12 Study demonstrates adding sintilimab to gemcitabine/platinum has clinical benefit
(International Association for the Study of Lung Cancer) Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic squamous cell non-small cell lung cancer, according to a study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 25, 2021 Category: Cancer & Oncology Source Type: news

Cancer symptoms: How to identify skin cancer when it is a squamous cell carcinoma
CANCER of the skin can fall into two categories: basal cell carcinoma and squamous cell carcinoma , with the latter being more dangerous. SCCs can become invasive, growing into deep layers of the skin and can metastasise. (Source: Daily Express - Health)
Source: Daily Express - Health - May 23, 2021 Category: Consumer Health News Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer
May 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated data from the Phase 1 CHRYSALIS study showing treatment with amivantamab in combination with lazertinib led to a median duration of response (DOR) of 9.6 months in chemotherapy-naïve patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib.[1] These data, which will be presented in an oral presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual ...
Source: Johnson and Johnson - May 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Gut health startup Viome gets breakthrough device designation for mRNA analysis tool
Viome has adapted its technology to search for the presence of oral squamous cell carcinoma and oropharyngeal cancer in users ’ saliva samples.    (Source: mobihealthnews)
Source: mobihealthnews - May 7, 2021 Category: Information Technology Source Type: news

Aryl hydrocarbon receptor suppresses immunity to oral cancer through immune checkpoint regulation
(Boston University School of Medicine) A new Boston University School of Public Health (BUSPH) study has identified for the first time how the aryl hydrocarbon receptor (AhR), an environmental chemical receptor, drives immunosuppression in oral squamous cell carcinoma (OSCC)--and that its removal from malignant cells can result in tumor rejection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

UCLA team discovers how to restrict growth, spread of head and neck cancers
(University of California - Los Angeles) Researchers from the UCLA School of Dentistry have discovered a key molecule that allows cancer stem cells to bypass the body's natural immune defenses, spurring the growth and spread of head and neck squamous cell cancers. Their study, conducted in mice, also demonstrates that inhibiting this molecule derails cancer progression and helps eliminate these stem cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 4, 2021 Category: Cancer & Oncology Source Type: news

UCLA team discovers how to restrict growth, spread of head and neck cancers
Researchers from the  UCLA School of Dentistry have discovered a key molecule that allows cancer stem cells to bypass the body’s natural immune defenses, spurring the growth and spread of head and neck squamous cell cancers. Their study, conducted in mice, also demonstrates that inhibiting this molecule derails cancer progression and helps e liminate these stem cells.  Published today in the journal Cell Stem Cell, the findings could help pave the way for more effective targeted treatments for this highly invasive type of cancer, which is characterized by frequent resistance to therapies, rapid metasta...
Source: UCLA Newsroom: Health Sciences - May 3, 2021 Category: Universities & Medical Training Source Type: news

New study provides insight in identifying, treating lung cancer at early stages
(Boston University School of Medicine) Lung carcinomas are the leading cause of cancer-related deaths in the United States and worldwide. Lung squamous cell carcinomas (non-small cell lung cancers that arise in the bronchi of the lungs and make up approximately 30 percent of all lung cancers) are poorly understood, particularly with respect to the cell type and signals that contribute to disease onset. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news

Response to Comment on "Tumor-initiating cells establish an IL-33-TGF-{beta} niche signaling loop to promote cancer progression"
Kamphuis et al. argue that macrophages accumulated in the proximity of tumor-initiating cells do not express the high-affinity immunoglobulin E receptor FcRIα. Although we cannot exclude the possibility of nonspecific binding of anti-FcRIα antibody (clone MAR-1), we provide evidence that macrophages in squamous cell carcinomas express FcRIα and that IL-33 induces FcRIα expression in bone marrow cell–derived macrophages. (Source: ScienceNOW)
Source: ScienceNOW - April 8, 2021 Category: Science Authors: Taniguchi, S., Elhance, A., Van Duzer, A., Kumar, S., Leitenberger, J., Oshimori, N. Tags: Immunology, Medicine, Diseases t-comment Source Type: news

Actinic Keratosis Diagnosis Ups Cumulative Risk for Skin Cancer
MONDAY, March 29, 2021 -- The annual increase in risk for cutaneous squamous cell carcinoma (cSCC) is higher for patients who have received a diagnosis of one or more actinic keratoses (AKs), according to a study published online March 24 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2021 Category: Pharmaceuticals Source Type: news

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers
By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from theUCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant.Their findings,  published online in the journal Molecular Cell, could help researchers develop more refined approaches to combatting highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat.Immunotherapy, which is used as a clinical treatment for various cancers, harnesses t...
Source: UCLA Newsroom: Health Sciences - March 23, 2021 Category: Universities & Medical Training Source Type: news

2020 British Guidelines for Cutaneous Squamous Cell Carcinoma 2020 British Guidelines for Cutaneous Squamous Cell Carcinoma
Review a summary of the latest updates regarding clinical management of cutaneous squamous cell carcinoma, as presented in the 2020 guidelines from the British Association of Dermatologists.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Oncotarget: Genomic and neoantigen evolution in head and neck squamous cell carcinoma
(Impact Journals LLC) In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 17, 2021 Category: Cancer & Oncology Source Type: news

Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care A Phase II ... Biopharmaceuticals, Oncology, Licensing Merck KGaA, Debiopharm, xevinapant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2021 Category: Pharmaceuticals Source Type: news

How Serious Is A Squamous Cell Carcinoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - March 1, 2021 Category: General Medicine Source Type: news

GERD Linked to Squamous Cell Cancers of Larynx, Esophagus
MONDAY, Feb. 22, 2021 -- Gastroesophageal reflux disease (GERD) appears to be associated with an increased risk for squamous cell cancers of the larynx and esophagus, according to a study published online Feb. 22 in Cancer. Shao-Ming Wang, Ph.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2021 Category: Pharmaceuticals Source Type: news

Expert Offers Tips for Sorting Out Pink Lesions on Dermoscopy Expert Offers Tips for Sorting Out Pink Lesions on Dermoscopy
"How can dermoscopy help us distinguish between Spitz nevus, melanoma, clear cell acanthoma, psoriasis, basal cell carcinoma, and squamous cell carcinoma?"Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 2, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Gene Test Helps Inform Management of High-Risk SCC Patients Gene Test Helps Inform Management of High-Risk SCC Patients
Emerging data support the clinical validity and use of DecisionDx-SCC as a prognostic 40-gene expression profile test for patients with high-risk squamous cell carcinoma.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 1, 2021 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Cemiplimab for advanced cutaneous squamous cell carcinoma: survival gains at acceptable cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

New Amivantamab Data from CHRYSALIS Study Show Robust Clinical Activity and Durable Responses in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer and EGFR Exon 20 Insertion Mutations
January 28, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 1 CHRYSALIS study, which evaluated amivantamab in patients with metastatic or unresectable non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on or after platinum-based chemotherapy.1 These data were presented for the first time in an oral presentation at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore. The key findings sho...
Source: Johnson and Johnson - January 29, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma
(NRG Oncology) A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2021 Category: Cancer & Oncology Source Type: news

Does Squamous Cell Cancer Turn into Melanoma
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 26, 2021 Category: General Medicine Source Type: news

Janssen to Highlight Commitment to Lung Cancer Science and Innovation with Eight Data Presentations at the International Association for the Study of Lung Cancer ’s 2020 World Conference on Lung Cancer
January 12, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that eight company-sponsored presentations, including two oral presentations, will be featured at the International Association for the Study of Lung Cancer’s (IASLC) 2020 World Conference on Lung Cancer (WCLC) Singapore taking place virtually January 28-31, 2021. The presentations include updated data from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab in patients with NSCLC and EGFR exon 20 insertion mutations and two studies that characterize the high unmet need and lack of stand...
Source: Johnson and Johnson - January 13, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Oncotarget: PD-1/PD-L1 expression in anal squamous intraepithelial lesions
(Impact Journals LLC) Dr. Margot Bucau from The H ô pital Bichat-Claude Bernard said, " Anal intraepithelial neoplasia (AIN) is the precursor lesion for anal squamous cell carcinomas (ASCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2021 Category: International Medicine & Public Health Source Type: news

Proteogenomics offers insight to treating head and neck squamous cell carcinoma
(Baylor College of Medicine) A new study identifies three molecular subtypes in head and neck squamous cell carcinoma (HNSCC) that could be used to better determine appropriate treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2021 Category: International Medicine & Public Health Source Type: news

Researchers aim AI at rising oral cancers with $3.3M grant from National Cancer Institute
(Case Western Reserve University) Researchers at Case Western Reserve University and partners in the United States and India are applying artificial intelligence (AI) to help physicians customize treatments for patients with the most common oral cancer, known as squamous cell carcinomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 5, 2021 Category: Cancer & Oncology Source Type: news

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news